{"entity":{"type":"insider","cik":"0001625110","url":"/insider/0001625110","json_url":"/insider/0001625110.json","name":"Dorval Allison","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":11,"n_filings":11,"first":"2020-01-29","last":"2026-06-15","span_basis":"filed_date"},"name_variants":[{"name":"Dorval Allison","source":"filing","n_filings":11,"first_seen":"2020-01-29","last_seen":"2026-06-15"}],"transactions":[{"id":5881050,"accession":"0001437749-26-020703","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001437749-26-020703","line_url":"/filing/0001437749-26-020703#line-2","is_derivative":false,"issuer_cik":"0001401667","issuer_name":"PUMA BIOTECHNOLOGY, INC.","issuer_ticker":"PBYI","issuer_name_source":null,"issuer_url":"/issuer/0001401667","owner_cik":"0001625110","owner_name":"Dorval Allison","owner_display_name":"Dorval Allison","owner_url":"/insider/0001625110","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11610.0,"shares_display":"11,610","price_per_share":7.1989,"price_display":"7.20","price_state":"stated","total_value":83579.229,"total_display":"83,579.23","total_whole":"83,579","shares_owned_after":90780.0,"shares_owned_after_display":"90,780","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-12","filed_date":"2026-06-15","scope":"insider"},{"id":4468307,"accession":"0001437749-25-020713","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001437749-25-020713","line_url":"/filing/0001437749-25-020713#line-1","is_derivative":false,"issuer_cik":"0001401667","issuer_name":"PUMA BIOTECHNOLOGY, INC.","issuer_ticker":"PBYI","issuer_name_source":null,"issuer_url":"/issuer/0001401667","owner_cik":"0001625110","owner_name":"Dorval Allison","owner_display_name":"Dorval Allison","owner_url":"/insider/0001625110","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11610.0,"shares_display":"11,610","price_per_share":3.4,"price_display":"3.40","price_state":"stated","total_value":39474.0,"total_display":"39,474.00","total_whole":"39,474","shares_owned_after":75390.0,"shares_owned_after_display":"75,390","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-13","filed_date":"2025-06-17","scope":"insider"},{"id":4526160,"accession":"0000950170-25-050559","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-050559","line_url":"/filing/0000950170-25-050559#line-2","is_derivative":false,"issuer_cik":"0001625110","issuer_name":"Verve Therapeutics, Inc.","issuer_ticker":"VERV","issuer_name_source":null,"issuer_url":"/issuer/0001625110","owner_cik":"0001625110","owner_name":"Dorval Allison","owner_display_name":"Dorval Allison","owner_url":"/insider/0001625110","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3350.0,"shares_display":"3,350","price_per_share":4.15,"price_display":"4.15","price_state":"stated","total_value":13902.5,"total_display":"13,902.50","total_whole":"13,903","shares_owned_after":13280.0,"shares_owned_after_display":"13,280","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-04-02","filed_date":"2025-04-03","scope":"insider"},{"id":2429898,"accession":"0000950170-24-132799","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-132799","line_url":"/filing/0000950170-24-132799#line-2","is_derivative":false,"issuer_cik":"0001625110","issuer_name":"Verve Therapeutics, Inc.","issuer_ticker":"VERV","issuer_name_source":null,"issuer_url":"/issuer/0001625110","owner_cik":"0001625110","owner_name":"Dorval Allison","owner_display_name":"Dorval Allison","owner_url":"/insider/0001625110","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":555.0,"shares_display":"555","price_per_share":5.64,"price_display":"5.64","price_state":"stated","total_value":3130.2,"total_display":"3,130.20","total_whole":"3,130","shares_owned_after":5380.0,"shares_owned_after_display":"5,380","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-02","filed_date":"2024-12-03","scope":"insider"},{"id":2487795,"accession":"0001437749-24-020566","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001437749-24-020566","line_url":"/filing/0001437749-24-020566#line-1","is_derivative":false,"issuer_cik":"0001401667","issuer_name":"PUMA BIOTECHNOLOGY, INC.","issuer_ticker":"PBYI","issuer_name_source":null,"issuer_url":"/issuer/0001401667","owner_cik":"0001625110","owner_name":"Dorval Allison","owner_display_name":"Dorval Allison","owner_url":"/insider/0001625110","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11000.0,"shares_display":"11,000","price_per_share":3.3724,"price_display":"3.37","price_state":"stated","total_value":37096.4,"total_display":"37,096.40","total_whole":"37,096","shares_owned_after":33000.0,"shares_owned_after_display":"33,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-13","filed_date":"2024-06-17","scope":"insider"},{"id":8671098,"accession":"0000950170-23-067358","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-23-067358","line_url":"/filing/0000950170-23-067358#line-2","is_derivative":false,"issuer_cik":"0001625110","issuer_name":"Verve Therapeutics, Inc.","issuer_ticker":"VERV","issuer_name_source":null,"issuer_url":"/issuer/0001625110","owner_cik":"0001625110","owner_name":"Dorval Allison","owner_display_name":"Dorval Allison","owner_url":"/insider/0001625110","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":554.0,"shares_display":"554","price_per_share":11.45,"price_display":"11.45","price_state":"stated","total_value":6343.3,"total_display":"6,343.30","total_whole":"6,343","shares_owned_after":4060.0,"shares_owned_after_display":"4,060","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-29","filed_date":"2023-12-01","scope":"insider"},{"id":7811449,"accession":"0001437749-23-017604","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001437749-23-017604","line_url":"/filing/0001437749-23-017604#line-2","is_derivative":false,"issuer_cik":"0001401667","issuer_name":"PUMA BIOTECHNOLOGY, INC.","issuer_ticker":"PBYI","issuer_name_source":null,"issuer_url":"/issuer/0001401667","owner_cik":"0001625110","owner_name":"Dorval Allison","owner_display_name":"Dorval Allison","owner_url":"/insider/0001625110","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":3.45,"price_display":"3.45","price_state":"stated","total_value":34500.0,"total_display":"34,500.00","total_whole":"34,500","shares_owned_after":17000.0,"shares_owned_after_display":"17,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-13","filed_date":"2023-06-15","scope":"insider"},{"id":6548971,"accession":"0001209191-22-059211","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-059211","line_url":"/filing/0001209191-22-059211#line-2","is_derivative":false,"issuer_cik":"0001625110","issuer_name":"Verve Therapeutics, Inc.","issuer_ticker":"VERV","issuer_name_source":null,"issuer_url":"/issuer/0001625110","owner_cik":"0001625110","owner_name":"Dorval Allison","owner_display_name":"Dorval Allison","owner_url":"/insider/0001625110","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":554.0,"shares_display":"554","price_per_share":22.1,"price_display":"22.10","price_state":"stated","total_value":12243.4,"total_display":"12,243.40","total_whole":"12,243","shares_owned_after":2186.0,"shares_owned_after_display":"2,186","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-29","filed_date":"2022-12-01","scope":"insider"},{"id":5343923,"accession":"0001104659-21-023961","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-21-023961","line_url":"/filing/0001104659-21-023961#line-1","is_derivative":false,"issuer_cik":"0001625110","issuer_name":"Voyager Therapeutics, Inc.","issuer_ticker":"VYGR","issuer_name_source":null,"issuer_url":"/issuer/0001625110","owner_cik":"0001625110","owner_name":"Dorval Allison","owner_display_name":"Dorval Allison","owner_url":"/insider/0001625110","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3186.0,"shares_display":"3,186","price_per_share":7.55,"price_display":"7.55","price_state":"stated","total_value":24054.3,"total_display":"24,054.30","total_whole":"24,054","shares_owned_after":45894.0,"shares_owned_after_display":"45,894","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-11","filed_date":"2021-02-16","scope":"insider"},{"id":4986856,"accession":"0001104659-21-004320","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-21-004320","line_url":"/filing/0001104659-21-004320#line-1","is_derivative":false,"issuer_cik":"0001625110","issuer_name":"Voyager Therapeutics, Inc.","issuer_ticker":"VYGR","issuer_name_source":null,"issuer_url":"/issuer/0001625110","owner_cik":"0001625110","owner_name":"Dorval Allison","owner_display_name":"Dorval Allison","owner_url":"/insider/0001625110","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2942.0,"shares_display":"2,942","price_per_share":8.62,"price_display":"8.62","price_state":"stated","total_value":25360.04,"total_display":"25,360.04","total_whole":"25,360","shares_owned_after":49080.0,"shares_owned_after_display":"49,080","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-12","filed_date":"2021-01-14","scope":"insider"},{"id":3207213,"accession":"0001104659-20-008190","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-20-008190","line_url":"/filing/0001104659-20-008190#line-1","is_derivative":false,"issuer_cik":"0001625110","issuer_name":"Voyager Therapeutics, Inc.","issuer_ticker":"VYGR","issuer_name_source":null,"issuer_url":"/issuer/0001625110","owner_cik":"0001625110","owner_name":"Dorval Allison","owner_display_name":"Dorval Allison","owner_url":"/insider/0001625110","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3128.0,"shares_display":"3,128","price_per_share":13.36,"price_display":"13.36","price_state":"stated","total_value":41790.08,"total_display":"41,790.08","total_whole":"41,790","shares_owned_after":24522.0,"shares_owned_after_display":"24,522","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-01-21","filed_date":"2020-01-29","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":11,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":11,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":11},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001401667","name":"PUMA BIOTECHNOLOGY, INC.","url":"/issuer/0001401667","role":"Director","n_filings":4,"first_seen":"2023-06-15","last_seen":"2026-06-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001840574","name":"Verve Therapeutics, Inc.","url":"/issuer/0001840574","role":"Officer (Chief Financial Officer)","n_filings":4,"first_seen":"2022-12-01","last_seen":"2025-04-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001640266","name":"Voyager Therapeutics, Inc.","url":"/issuer/0001640266","role":"Officer (Chief Financial Officer)","n_filings":3,"first_seen":"2020-01-29","last_seen":"2021-02-16"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001625110","retrieved_at":"2026-08-26T07:58:40+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}